|Mr. Gregory J. Flesher||CEO & Director||N/A||N/A||1970|
|Dr. Catherine C. Turkel PharmD, MBA, Ph.D.||Pres||N/A||N/A||1961|
|Mr. Jon Kuwahara CPA||Sr. VP of Fin. & Admin.||N/A||N/A||1965|
Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Novus Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.